Introduction {#Sec1}
============

While antibiotics are one of the greatest inventions of the twentieth century, their potential side effects are being increasingly recognized. In addition to concerns on the emergence of bacterial resistance, it has been suggested that antibiotic-induced changes to the intestinal flora could have serious and long-lasting consequences for human physiology \[[@CR1], [@CR2]\]. Paradoxically, antibiotic treatment can increase susceptibility to opportunistic and nosocomial infections by affecting the resistance of the intestinal microbiota to colonization \[[@CR3]\]. A low-diversity community with limited resilience allows pathogens like *Clostridium difficile* and vancomycin-resistant enterococci to grow unrestrictedly \[[@CR4]\]. Additionally, decreased gut microbial diversity has been associated with pathogenic conditions, such as inflammatory bowel disease and increased mortality following allogeneic hematopoietic stem cell transplantation (HSCT) \[[@CR2], [@CR5]\]. Physiological functions of the microbiota, such as the metabolism of carbohydrates and production of vitamins, may be lost as well.

A decreased gut microbial diversity could be of particular relevance for critically ill patients, as the vast majority of patients in an intensive care unit (ICU) are treated with antibiotics. A prospective point prevalence study involving 1265 ICUs across the world found that on any given day 75% of patients admitted to these ICUs received antibiotics \[[@CR6]\]. In The Netherlands, systemic decontamination of the digestive tract (SDD), consisting of topical application of non-absorbable antibiotics and a short course of systemic cephalosporins, is common practice in ICUs \[[@CR7], [@CR8]\]. SDD is a much-debated policy, with reduced infection rates and mortality as potential benefits and increased antimicrobial resistance as potential drawback. While the aim of SDD is to prevent colonization with potential pathogenic microorganisms while preserving anaerobic bacteria, its effect on the composition of the intestinal microbiota as a whole is ill-defined.

Recent advances, such as the implementation of fecal transplantation as therapy for *C. difficile* infection, suggest that it may be possible to monitor, prevent, or even cure disease by modulating the intestinal microbiota \[[@CR9]--[@CR11]\]. First, however, more knowledge is needed on the composition of the gut microbiota in critically ill patients to better understand the clinical consequences of microbiota disturbances and thus determine which patients might benefit from microbiota-based therapies \[[@CR9]\].

Based on previous studies, we hypothesized that microbial diversity would be extremely low in critically ill patients and that low diversity would be associated with worse clinical outcome \[[@CR5], [@CR12], [@CR13]\]. In this pilot study we describe the phylogenetic composition of the fecal microbiota in a cohort of critically ill patients using 16S rRNA gene sequence analysis and compare the results in both septic and non-septic critically ill patients with those in healthy subjects. We also explored possibilities to correlate microbiota-derived markers with clinical outcome parameters.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

This study was part of a large prospective observational study in critically ill patients admitted to the ICU \[Molecular Diagnosis and Risk Stratification of Sepsis (MARS) study; clinicaltrials.gov identifier NCT01905033\] \[[@CR14]\]. Thirty-four randomly selected adult patients who were admitted to the ICU of the Academic Medical Center (Amsterdam, The Netherlands) between October 2012 and November 2013 were included. Patients who were transferred from other ICUs or had an expected length of ICU stay of \<24 h were excluded. All patients met at least two of the following criteria: body temperature of ≤36 or ≥38 °C, tachycardia of \>90/min, tachypnea of \>20/min or partial pressure of carbon dioxide (pCO~2~) of \< 4.3 kPA, and leukocyte count of \<4 × 10E9/L or \>12 × 10E9/L \[[@CR15]\]. Sepsis was defined when the inclusion criteria were associated with suspected infection within 24 h after ICU admission, with subsequent systemic therapeutic administration of antibiotics to the patient \[[@CR15]\]. Sequential Organ Failure Assessment scores were recorded daily. Definitions of acute kidney injury (AKI) or acute respiratory distress syndrome (ARDS) were used exactly as described previously \[[@CR16], [@CR17]\]. Data from the municipal personal records database were used to calculate long-term survival. The control group consisted of15 healthy, non-smoking human subjects who had not taken antibiotics during the previous year (ClinicalTrials.gov identifier NCT02127749) \[[@CR18]\]. Written informed consent was obtained from all healthy subjects and patients or their legal representative. Ethical approval for both the patient and healthy subject studies was received from the Medical Ethics Committee of the Academic Medical Center in Amsterdam, and all research was conducted in accordance with the declaration of Helsinki.

Intestinal microbiota analysis {#Sec4}
------------------------------

Fresh stool samples were stored at 4 °C and transferred to −80 °C within 24 h of collection. Samples were processed for 16S rRNA gene sequencing exactly as described by Lankelma et al. \[[@CR18]\]. DNA was isolated using a bead-beating protocol \[[@CR19]\]. The V1--V2 region of the bacterial 16S rRNA gene was amplified in a two-step protocol using universal primers 27F and 338R and sequenced on the Illumina MiSeq sequencing platform (Illumina, San Diego, CA). Full methods are available in Electronic Supplementary Material (ESM) File 1. The number of reads per sample and taxonomic distribution of the reads are specified in ESM File 2. A canonical correspondence analysis was performed using the Canoco 5 software package (Biometris, Wageningen, The Netherlands).

To investigate whether microbiota diversity was associated with clinical outcome, we divided the cohort into two groups, namely, one with low bacterial diversity (Shannon index \< 4.0) and one with normal diversity (Shannon index \> 4.0). Previous studies have used similar arbitrary cutoffs \[[@CR5], [@CR20]\]; the present cutoff is based on the range of diversity in healthy controls.

Statistical analysis {#Sec5}
--------------------

Continuous nonparametric data were analyzed using a Mann--Whitney *U* or Kruskal--Wallis test, and the results are presented as the median and interquartile range (IQR). Continuous parametric data, presented as numbers and percentage or as the mean ± standard deviation, were analyzed with a student's *t* test or analysis of variance. Categorical data were analyzed using a Chi-square test. All data analyses were performed with R studio built under R version 3.2.3 (R Core Team 2013; R Foundation for Statistical Computing, Vienna, Austria). A *p* value of \<0.05 was considered to be statistically significant. Figures were created using Graphpad Prism (GraphPad Software, San Diego, CA).

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

A single fecal sample was collected from 34 critically ill patients (mean age 64 years; 48% male) between 1 and 21 days after ICU admittance \[median 4.5 (IQR 2.8--7) days; ESM Tables S1 and S2\]. Of these 34 patients, 25 were admitted because of sepsis and one had a non-infectious diagnosis (ESM Table S1). Fifteen healthy subjects served as controls.

Microbial composition of fecal samples {#Sec8}
--------------------------------------

Compared to healthy subjects, the stool microbiota showed a highly abnormal composition in most patients, based on both the highest bacterial taxonomic ranks (phylum level) and lowest detectable ranks (genus level).

### Phylum level {#Sec9}

To obtain a global view of the fecal microbiota in critically ill patients, we first investigated microbiota composition at the phylum level (Fig. [1](#Fig1){ref-type="fig"}). Firmicutes and Bacteroidetes are the predominant phyla in a stable intestinal microbiota, which was confirmed in our healthy subjects with these two phyla combined constituting 89--98% of all bacteria. However, in 12 of the 34 patients, Firmicutes and Bacteroidetes constituted \<89% of all bacteria and even constituted as low as \<1% in one sample (*p* \< 0.0001, healthy controls vs. ICU patients). This was the case in both septic and non-septic patients. A relative high abundance of Proteobacteria was observed in approximately one-third of patients (*p* = 0.02, healthy controls vs. ICU patients). This phylum of Gram-negative bacteria includes many pathogenic and lipopolysaccharide-containing bacteria, such as *Escherichia*. There was a trend towards an increased ratio of Gram-negative to Gram-positive bacteria in ICU patients (*p* = 0.0658, healthy vs. ICU patients).Fig. 1High interindividual diversity in fecal microbiota composition at the phylum level in both septic and non-septic critically ill patients. A single fecal sample was collected from septic and non-septic intensive care unit (ICU) patients and healthy subjects. Total bacterial 16S rDNA was isolated and sequenced to investigate the bacterial composition of these samples. Each*bar* represents the microbiota composition of one individual patient (patient number indicated at*bottom of each bar*) at the phylum level, which is the highest bacterial taxonomic rank. Data are presented as the percentage of total 16S rDNA reads in each sample;*colors* indicate different phyla. Patients are grouped according to their main diagnosis. *Table* shows which classes of antibiotics each patient received during their stay in the intensive care unit prior to fecal sampling.*Topical P/T/A* Topical application of polymyxin E, tobramycin, and amphotericin B. None of the healthy subjects had received antibiotics for at least 12 months prior to fecal sampling

While it is known that intestinal microbiota is highly personalized, some very striking individual patterns were observed. The fecal sample of patient no. 12 (who had an abdominal *Escherichia coli* sepsis) showed a high abundance of Synergistetes and those of patient nos. 4 and 18 revealed a high abundance of Verrucomicrobia (discussed in more detail further in the text.

### Genus level {#Sec10}

Our analysis of bacterial composition at the genus level (ESM Fig. S1) revealed an even greater interpatient diversity than that seen at the phylum level. Septic and non-septic patients did however share some common characteristics when compared to healthy subjects. Most notably, several key bacterial genera that each represent around 5% of the microbiota in healthy subjects had disappeared almost completely, including *Faecalibacterium*,*Blautia*, *Ruminococcus*, *Subdoligranulum* and *Pseudobutyrivibrio* (all *p* \< 0.0001, healthy controls vs. ICU patients).

No single bacterial genus colonized \>50% of the microbiota in the healthy subjects, whereas this did occur in 13 of the 34 patients, with one genus comprising even \>75% of the microbiota in four patients (ESM Fig. S1). These dominating genera included the usual suspects, such as *Enterococcus* (*p* = 0.0002 healthy controls vs. ICU patients). Members of *Staphylococcus* and *Escherichia/Shigella* were also significantly more abundant in the ICU patients, especially in the abdominal sepsis group (*p* = 0.042 and *p* = 0.049, respectively, healthy controls vs. ICU patients; *p* = 0.0048 and *p* = 0.001, respectively, healthy controls vs. ICU patients with abdominal sepsis). A canonical correspondence analysis to deduce the major driving forces in the variability within all microbial data indicated that fecal microbiota from abdominal sepsis patients differed the most from that of the other patient groups (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2High interindividual diversity in septic critically ill patients with sepsis. **a** Pearson correlations were calculated to investigate the level of similarity in microbiota composition between patients with a critical illness of different origin (sepsis originating from lung, abdomen, urinary tract, or other location and non-septic critical illness). Patient groups are indicated by *colors*. Healthy individuals are depicted as additional control group. Data are presented as mean ± standard deviation. \**p* \< 0.05, \*\**p* \< 0.001 vs. healthy controls; *p* = 0.0005 for all septic patients vs. healthy controls. **b** A canonical correspondence analysis to deduce the major driving forces (*Axis 1*,*Axis 2*) in the variability within the microbial data of all ICU patients, thereby indicating whether samples are alike (in close proximity to each other) or not (increased distance). The variance is indicated as percentages. *Symbols/colors* represent patient groups as indicated (see**a**)

Surprisingly, in some patients bacteria belonging to *Lactobacillus* spp. (*p* = 0.051, healthy controls vs. ICU patients with pulmonary sepsis; *p* = 0.06, healthy controls vs. ICU patients with abdominal sepsis) and *Akkermansia* spp. (of the phylum Verrucomicrobia; no statistically significant correlation with sepsis) were abundantly present. Notably, *A. muciniphila* is known for immune stimulation and barrier function improvement \[[@CR21], [@CR22]\]. The phylum Synergistetes consists of anaerobic Gram-negative bacteria that have been associated with periodontal disease; those in sample 12 belong to the genus *Pyramidobacter*. The significance of *Pyramidobacter* in fecal microbiota is as yet unknown, but the oral isolate *P. piscolens* is known to produce hydrogen sulphide, which is implied in compromising gut barrier function \[[@CR22], [@CR23]\]. Overall, the similarity between samples from septic patients (Pearson correlation) was significantly lower than that of controls (*p* = 0.0005 healthy controls vs. septic patients; Fig. [2](#Fig2){ref-type="fig"}).

In patients undergoing allogeneic HSCT, intestinal domination by vancomycin-resistant enterococci precedes bloodstream infection with these bacteria \[[@CR24]\]. We did not observe any correspondence between intestinal abundance and clinical infections (data not shown). Likewise, no cases of *C. difficile* were recorded.

### Antibiotics {#Sec11}

All patients received SDD consisting of an oral paste and solution containing non-absorbable polymyxin E, tobramycin, and amphotericin B as well as a third-generation cefalosporin administered intravenously, unless the latter was deemed unnecessary by the treating physician as the patient was already being treated with another broad-spectrum antibiotic (Fig. [1](#Fig1){ref-type="fig"}). All septic patients were treated with additional antibiotics, varying from one to ten different classes of antimicrobial agents (Fig. [1](#Fig1){ref-type="fig"}; detailed description in ESM Table S2). Septic patients were treated with a significantly higher number of antibiotic classes than were non-septic critically ill patients (*p* \< 0.01), but no differences in microbiota composition were observed between these two groups, both at the phylum and genus levels.

Association between microbiota composition and clinical outcome parameters {#Sec12}
--------------------------------------------------------------------------

To explore whether microbiota-related markers could be related to outcome parameters, we used three parameters that are commonly used to describe the microbiota, namely, bacterial diversity, the Firmicutes/Bacteroidetes ratio (*F/B*-ratio), and the Gram-positive/Gram-negative bacteria ratio \[[@CR5], [@CR11], [@CR25], [@CR26]\].

We expected ultra-low bacterial diversity in our patient cohort based on the exposure of these patients to antibiotics and data reported from earlier studies \[[@CR5], [@CR13]\]. The critically ill patients in our study had significantly lower bacterial diversity than the control subjects (*p* \< 0.0001; Fig. [3](#Fig3){ref-type="fig"}). There was no correlation between the number of antibiotic classes that a patient had received and bacterial diversity (Fig. [3](#Fig3){ref-type="fig"}), nor between the number of days between admission and fecal sampling and bacterial diversity (data not shown). When the cohort was divided into two groups with low bacterial diversity (Shannon index \< 4.0) and normal diversity (Shannon index \> 4.0), there was no intergroup difference in the occurrence of complications such as AKI and ARDS or length of ICU and hospital stay (Fig. [3](#Fig3){ref-type="fig"}; ESM Table S3). In accordance with these results, both short- and long-term mortality were not associated with microbiota diversity. Both patient groups were comparable in terms of baseline characteristics, severity of disease, and classes of antibiotics received prior to fecal sampling (Table [1](#Tab1){ref-type="table"}).Fig. 3Decreased intestinal microbiota diversity in critically ill patients is not associated with survival in an exploratory setting. **a** Microbiota diversity, presented as the Shannon index, was calculated from 15 healthy subjects, as well as from all 34 critically ill patients. Data are presented as *dot plot* with the mean (*solid horizontal line*). \*\*\*\**p* \< 0.0001. **b** Shannon diversity from all 34 patient samples plotted against the number of different antibiotic classes (categorized as in Fig. [1](#Fig1){ref-type="fig"}) that a patient had received prior to fecal sampling. **c** Based on the range in diversity in healthy subjects, the patient cohort was split into two groups: Shannon index \<4 (normal diversity) and Shannon index \>4 (high diversity), for which a 90-day Kaplan--Meier survival plot is shown. *Numbers below the curve* Patients at risk per group Table 1Baseline characteristics of patients with normal or high intestinal microbiota diversity and use of antibiotics prior to fecal samplingBaseline characteristicsNormal microbial diversity (Shannon index \< 4)High microbial diversity (Shannon index \> 4)*P* valuePatients1717Demographics  Age (years)65.12 ± 13.3762.94 ± 10.96  Gender (male)8 (47.1%)8 (47.1%)  Body mass index27.09 ± 5.7825.72 ± 4.33  Race (white)15 (88.2%)15 (88.2%)1Admission  Medical admission15 (88.2%)12 (70.2%)0.41  Length of hospital stay prior to ICU admission1 \[0--2\]0 \[0--2\]0.70  Admission diagnosis sepsis13 (76.5%)12 (70.6%)0.63Chronic comorbidity  None5 (29.4%)4 (23.5%)1  Cardiovascular compromise6 (35.3%)4 (23.5%)0.72  COPD2 (11.8%)2 (11.8%)1  Diabetes mellitus3 (17.6%)2 (11.8%)1  Hypertension8 (47.1%)6 (35.3%)0.74  Malignancy (non-metastatic solid)3 (17.6%)3 (17.6%)1  Renal insufficiency3 (17.6%)2 (11.8%)1  Respiratory insufficiency3 (17.6%)2 (11.8%)1  Modified Charlson Comorbidity Index^a^4 \[3--6\]4 \[3--5\]0.74Severity of disease on ICU admission  APACHE IV score71 \[59--91\]95 \[79--107\]0.079  APACHE APS62 \[47--80\]82 \[64--96\]0.12  SOFA score8 \[5.5--10\]8 \[5--10\]1  Mechanical ventilation12 (70.6%)15 (88.2%)0.40  Organ failure15 (88.2%)15 (88.2%)1  Number of organs failing    14 (23.4%)5 (29.4%)1    27 (41.2%)6 (35.3%)1    ≥34 (23.5%)4 (23.5%)1  Shock7 (41.2%)9 (52.9%)0.71Antibiotics used prior to sample^b^0.95Data are presented as the median with the interquartile range in square brackets, a number with/without the percentage in parenthesis, or as the mean ± standard deviation, as appropriate*APACHE* Acute Physiology and Chronic Health Evaluation, *APS* acute physiology score, *COPD* chronic obstructive pulmonary disease, *ICU* intensive care unit^a^Modified Charlson Index is calculated including age^b^Overall Chi-square test calculated for the number of patients per group that had received a class of antibiotics (as indicated in Fig. [1](#Fig1){ref-type="fig"})

The *F/B*-ratio was very recently reported to be associated with survival in critically ill patients \[[@CR12]\]. The *F/B*-ratio is known to vary widely in healthy subjects \[[@CR27]\], as was the case in our control subjects whose *F/B*-ratio ranged between 0.5 and 8.4 (median 2.4, IQR 1.1--5.0; Fig. [4](#Fig4){ref-type="fig"}). In 11 of our 34 patients the *F/B*-ratio was \<0.5, indicating a relative increase in Bacteroidetes; in six patients, Firmicutes were relatively increased (*F/B* \> 8.4). In five patients, no Bacteroidetes were detected at all, and the *F/B*-ratio could not be calculated. There was no difference in *F/B*-ratio between survivors and non-survivors when plotted at different time points (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Firmicutes/Bacteroidetes ratio (*F/B*-ratio) and Gram-positive/Gram-negative bacteria ratio are not associated with short- and long-term survival in an exploratory setting. **a** The *F/B*-ratio was calculated from healthy subjects (*dotted horizontal lines* range of*F/B*-ratio in healthy subjects) and from all 34 critically ill patients. and plotted against survival at 4 time points. **b** Survival data were collected at four time points: during ICU stay (*ICU*) and at 30 and 90 days and 1 year (*d30*, *d90*, *1y*, respectively).**c** The ratio of total Gram-positive/Gram-negative bacteria was calculated from healthy subjects (*dotted horizontal lines* range of ratio of Gram-positive/Gram-negative bacteria in health subjects. **d** Survival data collected at same time points as for**b**.**b**, **d** Data are presented as *box-and-whisker plots*, with median (*horizontal line in box*), interquartile range (*ends of box*), and range (*whiskers*). *Black boxes* Healthy subjects, *white boxes* surviving ICU patients, *gray boxes* non-surviving ICU patients

Similar to our results for the *F/B*-ratio, the Gram-positive/Gram-negative bacteria ratio varied widely in healthy subjects, ranging between 0.5 and 8.0. In 14 of the 34 patients this ratio was \<0.5, indicating a relative increase in Gram-negative bacteria (Fig. [4](#Fig4){ref-type="fig"}). In two patients, no Gram-negative bacteria were detected. No differences were found between survivors and non-survivors with respect to the Gram-positive/Gram-negative bacteria ratio (Fig. [4](#Fig4){ref-type="fig"}).

Discussion {#Sec13}
==========

In this pilot study we performed in-depth fecal microbiota analysis in critically ill patients. We observed marked shifts in fecal bacterial composition of these patients compared to healthy controls. However, a large interindividual diversity was observed at both the phylum and genus levels. No significant differences in microbiota composition were found between patient groups, although patients with an abdominal sepsis showed the strongest changes in relative abundance of *Staphylococcus* and *Escherichia/Shigella*. Low bacterial diversity was found in both septic and non-septic patients. In this small cohort, we found no associations between microbiota diversity, *F/B*-ratio, or Gram-positive/Gram-negative bacteria ratio and outcome parameters, such as the occurrence of complications or mortality.

A common feature in all critically ill patients was the disappearance of genera such as *Faecalibacterium*,*Blautia*,*Ruminococcus*,*Subdoligranulum*, and *Pseudobutyrivibrio.* These bacteria degrade complex plant polysaccharides that human cells cannot break down and convert them, for example, into acetate and butyrate, the latter of which is an important energy source for colonic epithelial cells \[[@CR22]\]. It is therefore plausible that any microbial disturbance in ICU patients indirectly reduces energy resources. Fecal acetate and butyrate have been shown to be at significantly lower levels in critically ill patients compared to healthy controls \[[@CR28]\]. The disappearance of *Faecalibacterium prausnitzii*, which has known anti-inflammatory properties \[[@CR25]\], could potentially promote an unfavorable inflammatory state in the gut. A decreased abundance of *Faecalibacterium* has been reported in patients with inflammatory bowel disease, psoriasis, and colon cancer \[[@CR29]--[@CR31]\]. SDD has also been reported to affect the numbers of these bacteria \[[@CR32]\]. This decrease in beneficial bacteria is in apparent conflict with the potential benefits of SDD in terms of decreased ICU-acquired infections and mortality. As the aim of SDD is to prevent colonization by potential pathogens while preserving anaerobic bacteria, further studies are clearly needed to assess the precise influence of SDD on the microbiota \[[@CR32]\]. It will be essential to take these effects into account in the ongoing debate on the use of SDD. In-depth knowledge of the fecal microbiota composition of ICU patients receiving SDD or not will be an important question for follow-up studies.

Knowledge of microbiota changes in critically ill patients has been identified as a key objective for ICU research \[[@CR33]\]. A large retrospective cohort study among 10,996 participants of the Health and Retirement Study--Medicare found a strong dose--response relationship between events known to result in microbial disturbance and subsequent hospitalization for severe sepsis \[[@CR34]\]. Recent hospitalization for an infection, and especially *C. difficile* infection, was associated with a higher incidence of rehospitalization for severe sepsis \[[@CR34]\]. No microbial analyses were performed in this study. In fact, surprisingly few studies have addressed the microbiota in ICU patients using in-depth sequencing techniques. Two small studies of 12 and 14 ICU patients, respectively, found large interindividual differences in microbiota composition, in line with our findings \[[@CR12], [@CR13]\].

A decreased intestinal diversity has been associated with numerous pathogenic conditions, ranging from *C. difficile* infection, obesity and inflammatory bowel disease to increased mortality following allogeneic HSCT \[[@CR2], [@CR5], [@CR11]\]. Our data confirm the expected low bacterial diversity in septic critically ill patients. Strikingly, a similar low diversity was observed in non-septic critically ill, despite great differences in antibiotic treatment. Antibiotics, proton-pump inhibitors, radiation, chemotherapeutics, and poor nutrition may all contribute to the loss of bacterial taxa.

An increased *F/B*-ratio has been correlated with obesity, asthma, and irritable bowel syndrome \[[@CR25], [@CR35]\] and also with ICU mortality in critically ill patients \[[@CR12]\]. Our data argue against the usefulness of the *F/B*-ratio as a microbiota marker in critically ill patients, as both Firmicutes and Bacteroidetes can be strongly but equally decreased. For example, patients no. 6 and 34 in our study had normal *F/B*-ratios, while still being colonized at 38 and 25%, respectively, with Proteobacteria. We also observed a relative increase in Gram-negative bacteria in 11 patients. A decreased Gram-positive/Gram-negative ratio may be indicative of an increased inflammatory gut status as Gram-negative bacteria produce lipopolysaccharides, some of which are powerful endotoxins.

This study has a number of limitations. As the study started in 2012, sepsis was not defined according to the most recently proposed criteria, including organ failure \[[@CR36]\]. However, most patients likely meet these criteria considering that we exclusively studied patients in need of intensive care \[[@CR36]\]. It should be emphasized that the sample size is limited and the heterogeneity of critically ill patients substantial; these two limitations make it challenging to establish a potential causal relationship between microbiota composition and prognosis. Furthermore, fecal sampling is trying, as many patients do not defecate. In future studies, rectal swabs could provide a suitable alternative as these have been shown to provide data comparable to stool samples \[[@CR37]\]. The single fecal sample studied here should be complemented by longitudinal analyses to provide a dynamic view of the microbiota. It should also be kept in mind that fecal samples do not provide information about the microbiota in the upper gastrointestinal tract. Lastly, the viral and fungal microbiomes were not addressed in this study. This should be a key area of future studies, as these may comprise an important part of the microbiota in ICU patients.

In summary, we found striking abnormalities of the intestinal microbiota in both septic and non-septic critically ill patients, with a large interindividual variation and low bacterial diversity. Numerous questions remain to be answered, including: To what extent does microbial disturbance influence dietary needs, metabolic status, intestinal permeability, and immunity in critically ill patients? Equally important is the question: How might the observed microbiota shifts be leveraged, not only by developing diagnostic and prognostic markers but also therapeutically? Fecal microbiota transplantation is a feasible and effective treatment option for severe *C. difficile* infection in the ICU \[[@CR38]\] and could also become the next big breakthrough in the fight against multi-drug resistant bacteria \[[@CR3]\]. Two case reports have recently been published on the successful use of fecal microbiota transplantation in patients with therapy-resistant sepsis and diarrhea \[[@CR39], [@CR40]\]. This success raises hope for simple and effective adjunctive therapies based on our expanding knowledge of the gut microbiota that might benefit critically ill patients.
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